Showing 1 - 10 of 914
This paper measures differences in the innovation performance of different types of firms in the pharmaceutical industry. We compare the innovation performance of incumbent firms with entrants, controlling for differences in the scale and scope of research, both at the firm level and at the...
Persistent link: https://www.econbiz.de/10015217462
This paper measures differences in the innovation performance of different types of firms in the pharmaceutical industry. We compare the innovation performance of incumbent firms with entrants, controlling for differences in the scale and scope of research, both at the firm level and at the...
Persistent link: https://www.econbiz.de/10005061689
This paper compares the innovation performance of established pharmaceutical firms and biotech companies, controlling for differences in the scale and scope of research. We develop a structural model to analyze more than 3,000 drug R&D projects advanced to pre-clinical and clinical trials in the...
Persistent link: https://www.econbiz.de/10008501715
Persistent link: https://www.econbiz.de/10008316277
Persistent link: https://www.econbiz.de/10003908978
Persistent link: https://www.econbiz.de/10003449162
This paper explored an unusually comprehensive dataset of more than 2,000 drug R&D projects all over the world during the 1990s. This enabled us to characterise several features of the innovation process in pharmaceuticals, particularly the different role and comparative R&D performance of the...
Persistent link: https://www.econbiz.de/10015217420
This paper explored an unusually comprehensive dataset of more than 2,000 drug R&D projects all over the world during the 1990s. This enabled us to characterise several features of the innovation process in pharmaceuticals, particularly the different role and comparative R&D performance of the...
Persistent link: https://www.econbiz.de/10005034980
Persistent link: https://www.econbiz.de/10002370467
This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries. We focus on the competition at the level of single chemical entities, distinguishing between original...
Persistent link: https://www.econbiz.de/10015217415